🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "significant breakthrough" in the fight against drug-resistant strains of the pathogen, according to researchers.

A Global Challenge

Gonorrhoea infections are escalating around the world, with figures suggesting in excess of 82 million new cases per year. Especially elevated rates are reported in Africa and countries within the WHO's designated area, which spans from China and Mongolia to New Zealand. Within England, cases have reached a record high, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The authorization of new treatments for gonorrhoea is an critical and opportune step in the face of growing infection rates, the spread of superbugs and the extremely scarce therapeutic options currently available.”

Public health authorities are increasingly worried about the rise in treatment-resistant strains. The WHO has designated it as a "critical concern". Recent surveillance showed that resistance to primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Therapies Gain Authorization

Zoliflodacin, also known as Nuzolvence, was authorized by the US Food and Drug Administration in mid-December for combating gonorrhoea. This infection can lead to serious health problems, including infertility. Scientists believe that focused deployment of this new drug will help delay the spread of drug resistance.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, also received approval in concurrent days. This medication, which is also used to treat urinary tract infections, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Partnership

This new treatment emerged from a unique collaborative effort for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to develop it.

“This approval marks a huge turning point in the therapy of highly resistant gonorrhoea, which previously has been staying ahead of antibiotic development.”

Testing Outcomes and Worldwide Availability

Based on data released by a major medical journal, zoliflodacin successfully treated over nine in ten of cases of the STI. This puts it on an equal footing with the existing first-line therapy, which combines an injection and a pill. The research enrolled hundreds of patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, GARDP has the ability to license and sell the drug in a wide range of regions with limited resources.

Clinicians treating patients have voiced positive views. Having a single-dose, oral treatment such as this is seen as a "critical tool" for gonorrhoea control. This is viewed as vital to lessen the impact of the disease for individuals and to halt the transmission of untreatable gonorrhoea around the world.